Abiomed Stock Forecast, Price & News

Abiomed (NASDAQ:ABMD) Frequently Asked Questions

Is Abiomed a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abiomed in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Abiomed stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABMD, but not buy additional shares or sell existing shares.
View analyst ratings for Abiomed or view top-rated stocks.

What stocks does MarketBeat like better than Abiomed?

Wall Street analysts have given Abiomed a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Abiomed wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Abiomed's next earnings date?

Abiomed is scheduled to release its next quarterly earnings announcement on Thursday, October 28th 2021.
View our earnings forecast for Abiomed.

How can I listen to Abiomed's earnings call?

Abiomed will be holding an earnings conference call on Thursday, October 28th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "5159829".

How were Abiomed's earnings last quarter?

Abiomed, Inc. (NASDAQ:ABMD) released its quarterly earnings data on Tuesday, August, 3rd. The medical equipment provider reported $1.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.06 by $0.35. The medical equipment provider had revenue of $252.59 million for the quarter, compared to analysts' expectations of $243.81 million. Abiomed had a net margin of 16.51% and a trailing twelve-month return on equity of 16.35%.
View Abiomed's earnings history.

How has Abiomed's stock been impacted by Coronavirus?

Abiomed's stock was trading at $151.13 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ABMD stock has increased by 132.5% and is now trading at $351.37.
View which stocks have been most impacted by COVID-19.

What guidance has Abiomed issued on next quarter's earnings?

Abiomed issued an update on its FY 2022 earnings guidance on Wednesday, September, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.03 billion-$1.05 billion, compared to the consensus revenue estimate of $1.02 billion.

What price target have analysts set for ABMD?

4 brokers have issued 1-year target prices for Abiomed's shares. Their forecasts range from $245.00 to $425.00. On average, they expect Abiomed's stock price to reach $363.75 in the next year. This suggests a possible upside of 3.5% from the stock's current price.
View analysts' price targets for Abiomed or view top-rated stocks among Wall Street analysts.

Who are Abiomed's key executives?

Abiomed's management team includes the following people:

• Michael R. Minogue, Chairman, President & Chief Executive Officer (LinkedIn Profile)
• David M. Weber, Chief Operating Officer & Senior Vice President
• Todd A. Trapp, Chief Financial Officer & Vice President
• Thorsten Sieß, Chief Technology Officer & Vice President
• Charles A. Simonton, Chief Medical Officer

What is Michael R. Minogue's approval rating as Abiomed's CEO?

96 employees have rated Abiomed CEO Michael R. Minogue on Glassdoor.com. Michael R. Minogue has an approval rating of 72% among Abiomed's employees.

Who are some of Abiomed's key competitors?

Some companies that are related to Abiomed include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Edwards Lifesciences (EW), Becton, Dickinson and (BDX), Boston Scientific (BSX), IDEXX Laboratories (IDXX), DexCom (DXCM), Baxter International (BAX), ResMed (RMD), STERIS (STE), Insulet (PODD), Hologic (HOLX) and Teleflex (TFX).
View all of ABMD's competitors.

What other stocks do shareholders of Abiomed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abiomed investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Align Technology (ALGN), Arista Networks (ANET), Intuitive Surgical (ISRG), Square (SQ), Netflix (NFLX), Adobe (ADBE) and salesforce.com (CRM).

What is Abiomed's stock symbol?

Abiomed trades on the NASDAQ under the ticker symbol "ABMD."

Who are Abiomed's major shareholders?

Abiomed's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Scout Investments Inc. (0.24%), State of Alaska Department of Revenue (0.06%), Pacer Advisors Inc. (0.01%), Taylor Cottrill Erickson & Associates Inc. (0.01%), Unigestion Holding SA (0.01%) and Stonnington Group LLC (0.01%). Company insiders that own Abiomed stock include Andrew J Greenfield, Dorothy E Puhy, Joseph Riccelli, Magdalena Yesil, Martin P Sutter, Michael R Minogue, Michael R Minogue and Paul Thomas.
View institutional ownership trends for Abiomed.

Which major investors are selling Abiomed stock?

ABMD stock was sold by a variety of institutional investors in the last quarter, including Unigestion Holding SA, State of Alaska Department of Revenue, and Pacer Advisors Inc.. Company insiders that have sold Abiomed company stock in the last year include Andrew J Greenfield, Joseph Riccelli, Magdalena Yesil, Martin P Sutter, Michael R Minogue, and Paul Thomas.
View insider buying and selling activity for Abiomed or view top insider-selling stocks.

Which major investors are buying Abiomed stock?

ABMD stock was bought by a variety of institutional investors in the last quarter, including Scout Investments Inc., CHICAGO TRUST Co NA, Taylor Cottrill Erickson & Associates Inc., Stonnington Group LLC, Fifth Third Bancorp, and Berman Capital Advisors LLC.
View insider buying and selling activity for Abiomed or or view top insider-buying stocks.

How do I buy shares of Abiomed?

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Abiomed's stock price today?

One share of ABMD stock can currently be purchased for approximately $351.37.

How much money does Abiomed make?

Abiomed has a market capitalization of $15.95 billion and generates $847.52 million in revenue each year. The medical equipment provider earns $225.52 million in net income (profit) each year or $4.94 on an earnings per share basis.

How many employees does Abiomed have?

Abiomed employs 1,725 workers across the globe.

Does Abiomed have any subsidiaries?

The following companies are subsidiares of Abiomed: ABD Holding Company, ABIOMED Athlone Ltd, ABIOMED Australia Pte. Ltd, ABIOMED Europe, ABIOMED Japan KK, ABIOMED Limited, ABIOMED R&D, ABIOMED SARL, ABIOMED Singapore Pte. Ltd, AIS GmbH Aachen Innovative Solutions, ECP Entwicklungsgesellschaft mbH, and Impella Cardiosystems.

When was Abiomed founded?

Abiomed was founded in 1981.

What is Abiomed's official website?

The official website for Abiomed is www.abiomed.com.

Where are Abiomed's headquarters?

Abiomed is headquartered at 22 CHERRY HILL DR, DANVERS MA, 01923.

How can I contact Abiomed?

Abiomed's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at (978) 646-1400 or via email at [email protected].